Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 4/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.52 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316456 | 0.85 | ACLY (0.50) | ACLYHDAC1HDAC2TBK1IKBKE | |
| SCHEMBL27716636 | 0.85 | KAT6A (0.45) | ACLYKAT6ASUCNR1HDAC1HDAC2 | |
| SCHEMBL2273063 | 0.85 | KAT6A (0.50) | KAT6ASERPINE1MEN1PKMKMT2A | |
| SCHEMBL1316515 | 0.84 | ACLY (0.49) | ACLYKAT6AHDAC1HDAC2TBK1 | |
| SCHEMBL2269037 | 0.83 | ACLY (0.59) | ACLYSUCNR1SERPINE1MEN1PKM | |
| SCHEMBL2271258 | 0.83 | ACLY (0.67) | ACLYSUCNR1MEN1KMT2A | |
| SCHEMBL4215412 | 0.83 | ACLY (0.52) | ACLYKAT6ATBK1FFAR4IKBKE | |
| SCHEMBL1316420 | 0.81 | ALDH1A1 (0.47) | ACLYKAT6ASUCNR1DHODHHDAC1 | |
| SCHEMBL2275720 | 0.81 | SUCNR1 (0.73) | ACLYSUCNR1SERPINE1MEN1PKM | |
| SCHEMBL1316086 | 0.81 | ALDH1A1 (0.46) | ACLYKAT6ASUCNR1DHODHHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094829-B | novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO.,LTD. (JP) | 2012-02-08 | — | — | CN | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101094829-A | Novel anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885KAT6A 491/4885SUCNR1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.